Global Anal Fissure Treatment Market, By Treatment (Nitrate Ointment, Calcium Channel Blockers, Botox Injections, Surgery, Others), Route of Administration (Oral, Topical, Others), Application (Intersphincteric Fistula, Transsphincteric Fistula, Suprasphincteric Fistula, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Anal Fissure Treatment Market Analysis and Size
The features responsible for the growth of anal fissure treatment market are the susceptible constipation population, wide adoption of sedentary life style and consumption of spicy, saturated and trans-fat food. The increasing advancements in the field of the anal fistula market in the region are most likely to increase the market growth during the forecast period. The increasing presence of competitors, awareness associated with GI diseases, product launches, and acquisitions boosts the market growth.
Data Bridge Market Research analyses a growth rate in the anal fissure treatment market in the forecast period 2023-2030. The expected CAGR of anal fissure treatment market is tend to be around 8.7% in the mentioned forecast period. The market is valued at USD 1296.23 million in 2022, and it would grow upto USD 2526.5 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Anal Fissure Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Nitrate Ointment, Calcium Channel Blockers, Botox Injections, Surgery, Others), Route of Administration (Oral, Topical, Others), Application (Intersphincteric Fistula, Transsphincteric Fistula, Suprasphincteric Fistula, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbvie, Inc (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Troikaa (India), RDD Pharma, Ltd (U.S.), Kyowa Kirin Co., Ltd (Japan), Cipla Inc. (U.S.), Ipsen Pharma (France), Sanofi (France), Boehringer Ingelheim International GmbH. (Germany), Lupin (India), Bliss GVS (India), SRS Life Sciences (Singapore), Healthy Life Pharma Private Limited (India), Geri-Care Pharmaceuticals Corp. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Anal fissure is also termed anal ulcer an anorectal disorder characterized by inflammation or tearing of lining of the lower rectum. It causes extreme pain and bleeding during bowel movement. The condition is not life threatening but considerably affects the quality of person’s life. This condition generally heals on its own in four to six weeks. The common treatments include dietary fibre, stool softeners, and creams to the affected area.
Anal Fissure Treatment Market Dynamics
Drivers
- Increasing Elderly Population and Unhealthy Lifestyle
On account of its increasing elderly population, the market is expected to grow at a highest speed. The Administration for Community Living states that the percentage of Americans 65 and older to be augmented to 21.6% by 2040 from 16% in 2019. The other primary factors causing the expansion of the market includes the wide adoption of sedentary lifestyle and a rise in the consumption of saturated and trans fats. Around 28% of adults or 1.4 billion people are living a sedentary lifestyle which is nearly more than 1 in 4 adults globally.
- Rising Demand of Oral Route of Administration
The oral segment is expected to have increasing market share by the end of 2031. Laxatives, painkillers, calcium channel blockers, stool softners are some of the oral drugs. Botulinum toxin A and nitroglycerin are some of the topical medications. As most of these pharmaceuticals are widely available over the counter, the oral treatment segment holds the highest market share. Laxatives are often used for treating childhood constipation. More than 3% of children worldwide suffer from functional constipation on the other hand, 10-23% of incidence are anticipated in North and South America. Thus, this boosts the market growth.
Opportunities
- Increasing Genetic Manufacturers and Healthcare Expenditure
Several technical improvements with new products being launched by the pharmaceutical and biotechnology industries each year due to the presence of several generic manufacturers. As per the National Investment Promotion & Facilitation Agency, the Indian pharmaceutical businesses produced more than 60,000 generic brands spanning 60 therapeutic areas, which includes generic drugs, API/bulk drugs, OTC medications, and others. In addition to this, increasing healthcare expenditure globally further increases the market growth. For instance, healthcare spending in China was around 5.35% in 2019 up from 5.07 in 2017. Thus, this boosts the market growth.
- Growing Product Launches and Awareness
The wide presence of competitors, awareness associated with GI diseases, product launches, and acquisitions increases the market growth. For instance, Cross Valley Health & Medicine celebrates National Colorectal Cancer Awareness Month every year on March. Every year, healthcare professionals take this month to provide their patients with extra education around diseases of the colon and rectum. People become more aware of diseases in the rectum as a result of such government initiatives and this is most likely to increase the market growth during the forecast period.
Restraints/Challenges
- Lack of skilled professionals
The absence of qualified professionals who cannot treat the patients with suitable treatments could limit the market growth during the forecast period 2023-2030.
- High Cost of Treatment
The growing expenditure associated with the medications impede the market growth. These inhibitors cost high and people in the developing and underdeveloped countries, lead to the under treatment of several patients. This impedes the market growth.
This anal fissure treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anal fissure treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Anal Fissure Treatment Market
COVID-19 had a significant impact on the anal fistula treatment market. For instance, according to the article published in 2021 under the title “Insights into the management of anorectal disease in the coronavirus 2019 disease era”, during the COVID-19 pandemic, there was a huge delay in the treatment of anal fistula, which led to an uncomfortable situation for patients. In many cases, outpatient exploration with proctoscopy, and seton placement, were the other options based on a previous study in Crohn’s disease patients. Patients having no history of anal fissures also witness symptoms of the condition because of the medications during COVID-19. As per the same source, the incidence of anal fissures had been witnessed in patients who had prior COVID-19 treatment. Thus, COVID-19 had a major impact on the anal fistula treatment market
Recent Development
- In 2022, Ossium Health, Inc. received the U.S. FDA acceptance of its Investigational New Drug (IND) application for OSSM-001, a mesenchymal stem cell (MSC) product used for the treatment of refractory perianal fistulas in patients suffering from Crohn’s disease.
- In 2022, Takeda released the first six-month interim analysis results from INSPIRE, wherein clinical remission was witnessed in 65% of patients in both cohorts who were assessed at 6 months. INSPIRE is a European, observational, multicenter, post-approval, open-enrollment study assessing the real-world effectiveness and safety of Alofisel (darvadstrocel) in patients suffering from Crohn’s disease (CD) and complex perianal fistulas
Global Anal Fissure Treatment Market Scope
The anal fissure treatment market is segmented on the basis of treatment, route of administration, application, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Nitrate Ointment
- Calcium Channel Blockers
- Botox Injections
- Surgery
- Others
Route of Administration
- Oral
- Topical
- Others
Application
- Intersphincteric Fistula
- Transsphincteric Fistula
- Suprasphincteric Fistula
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Anal Fissure Treatment Market Regional Analysis/Insights
The anal fissure treatment market is analyzed and market size insights and trends are provided by treatment, application, route of administration, end-users and distribution channel as referenced above.
The major countries covered in the anal fissure treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for anal fissure treatment market throughout the forecasted period because of the large patient population having inflammatory bowel diseases, early adoption of advanced technologies, and increasing healthcare expenditure by the public and private sectors in the studied region.
Asia-Pacific dominates the market because of the presence of generic companies and increasing awareness about anorectal diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Anal Fissure Treatment Market Share Analysis
The anal fissure treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to anal fissure treatment market
Key players operating in the anal fissure treatment market include:
- Abbvie, Inc (U.S.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Troikaa (India)
- RDD Pharma, Ltd (U.S.)
- Kyowa Kirin Co., Ltd (Japan
- Cipla Inc. (U.S.)
- Ipsen Pharma (France)
- Sanofi (France)
- Boehringer Ingelheim International GmbH. (Germany)
- Lupin (India)
- Bliss GVS (India)
- SRS Life Sciences (Singapore)
- Healthy Life Pharma Private Limited (India)
- Geri-Care Pharmaceuticals Corp. (U.S.)
SKU-